Showing posts with label premenopausal. Show all posts
Showing posts with label premenopausal. Show all posts
Friday, March 30, 2012
abstract: Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders: Publication year: 2012
Objective
The human epididymis protein 4 (HE4) is a novel biomarker for ovarian cancer. This study measured the HE4 and CA125 levels in women with benign gynecological disorders.
Study Design
Sera were obtained from women prior to surgery for a pelvic mass and HE4 and CA125 levels were determined. The proportions of patients with elevated biomarker levels were compared.
Results
There were 1042 women with benign disease. HE4 levels were less often elevated than CA125 (8% vs 29%) . A marked difference was observed in patients with endometriosis in which HE4 was elevated in 3% of patients and CA125 in 67% . Serous ovarian tumors were associated with elevated levels of HE4 in 8% of patients and CA125 in 20%; uterine fibroids in 8% vs 26% ; dermoids in 1% vs 21% ; and inflammatory disease in 10% vs 37% .
Conclusion
HE4 is elevated less frequently than CA125 in benign disease, particularly in premenopausal patients.
add your opinions
benign disease
,
CA-125
,
CA125
,
HE4
,
premenopausal
Monday, February 21, 2011
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CAL
Note: side effects
INTERPRETATION: ZA every 3 months is well tolerated and prevents rapid bone loss in premenopausal women that develop CIOF. Giving ZA with rather than 1 year after the start of adjuvant chemotherapy is the preferred sequence to prevent bone loss.
add your opinions
bone loss
,
bone mineral density
,
premenopausal
,
side effects
,
zoledronic acid
Sunday, February 20, 2011
Diagnostic performance of urgent referrals for suspected gynaecological malignancies.
PURPOSE: The objective of this study was to investigate the outcome of the urgent referrals with suspected gynaecological malignancy.
CONCLUSION: The overall predictive value of two-week wait referrals for suspected gynaecological malignancies is low. Refinement of the current referral guidelines is required with particular emphasis in the premenopausal women where the diagnostic performance of the urgent referrals is significantly poorer.
add your opinions
premenopausal
,
referrals
Wednesday, August 25, 2010
Subscribe to:
Posts
(
Atom
)